Molecular Biomarkers of Tumors: Advancing Genetic Studies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 1041

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA
Interests: chromosomes; human genetics; genomics; genetic analysis; DNA sequencing; sequencing DNA; medical genetics; molecular genetics; mutation
Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA
Interests: investigating the interaction of Alzheimer's disease and sleep disruption in various mouse models, including use of novel noninvasive technologies, immunohistochemistry and metabolomics

Special Issue Information

Dear Colleagues,

We invite researchers and clinicians to contribute to the Special Issue of Biomedicine, dedicated to "Molecular Biomarkers of Tumors: Advancing Genetic Studies." This Special Issue aims to explore the latest developments in the realm of molecular biomarkers, with a specific focus on genetic investigations in tumors.

In the age of precision medicine, understanding the genetic landscape of tumors is crucial for accurate diagnosis, prognosis, and treatment decisions. This Special Issue will encompass a diverse range of topics related to molecular biomarkers, such as the identification and validation of novel genetic markers in various tumor types, genomic profiling to unravel tumor heterogeneity, and the application of molecular biomarkers for early detection and personalized therapeutic approaches.

We welcome original research articles and reviews that present cutting-edge discoveries, methodologies, and clinical applications in the field of molecular biomarkers in oncology. Additionally, studies addressing the challenges of translating genetic findings into clinical practice will be highly valued.

By fostering collaboration among multidisciplinary researchers, this Special Issue aims to advance our knowledge of tumor biology and personalized medicine. Ultimately, this knowledge will contribute to the development of more effective and targeted cancer therapies, enhancing patient outcomes and overall quality of life.

Dr. Sainan Wei
Dr. Jing Di
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1965 KiB  
Article
Generation of a Specific Fluorescence In Situ Hybridization Test for the Detection of Ovarian Carcinoma Cells
by Amelie Limburg, Xueqian Qian, Bernice Brechtefeld, Nina Hedemann, Inken Flörkemeier, Christoph Rogmans, Leticia Oliveira-Ferrer, Nicolai Maass, Norbert Arnold, Dirk O. Bauerschlag and Jörg Paul Weimer
Biomedicines 2024, 12(6), 1171; https://doi.org/10.3390/biomedicines12061171 - 24 May 2024
Viewed by 300
Abstract
Examinations of ovarian cancer cells require the ability to identify tumor cells. Array-based comparative genome hybridization (aCGH) on 30 ovarian carcinomas (OC) identified three genomic loci (8q24.23; 17p12; 18q22.3) over- or under-represented in OC. A fluorescence in situ hybridization (FISH) probe of these [...] Read more.
Examinations of ovarian cancer cells require the ability to identify tumor cells. Array-based comparative genome hybridization (aCGH) on 30 ovarian carcinomas (OC) identified three genomic loci (8q24.23; 17p12; 18q22.3) over- or under-represented in OC. A fluorescence in situ hybridization (FISH) probe of these three loci is intended to identify tumor cells by their signal pattern deviating from a diploid pattern. Human DNA from these three loci is isolated from bacterial artificial chromosomes (BAC), amplified and labeled with fluorescent dyes. After a standard FISH procedure, 71 OC suspensions from primary tumors, three OC cell lines, three lymphocyte suspensions, and one mesenchymal cell line LP-3 are analyzed with a fluorescence microscope. On average, 15% of the lymphocytes deviate from the expected diploid signal pattern, giving a cut-off of 36%. If this value is exceeded, tumor cells are detected. The mesenchymal cell line LP-3 shows only 21% as a negative control. The OC cell lines as positive controls exceed this value at 38%, 67%, and 54%. Of the 71 OC primary cultures, four cases fell below this cut-off as false negatives. In the two-sample t-test, the percentages of conspicuous signal patterns differ significantly. Full article
(This article belongs to the Special Issue Molecular Biomarkers of Tumors: Advancing Genetic Studies)
Show Figures

Figure 1

Back to TopTop